The CV Devices Hub award funds a series of projects that will lead to the creation of a unique, one-stop Cardiovascular Device and Therapeutic Innovation Centre ‘CVDHub’.
This unique facility will act as the interface to facilitate the engagement of CV businesses across the UK through bespoke innovation support and will broker collaborations with London’s academic/scientific knowledge base. The CVDHub aims to support business competitiveness and to develop/deliver new CV products/technologies and to exploit the economic potential of the global cardiovascular device market (estimated value $65.7 billion; 9% annual growth rate).
The CVDHub will be physically located adjacent to QMUL’s medical science research base and the Barts Heart Centre, one of the largest cardiovascular hospitals in Europe with ~80k unique patient episodes per annum. Key objectives of the CVDHub include it being seen as a national gateway that promotes HEI-business collaboration, R&D/inward investment, job creation and the platform for the development and delivery of 3 novel cardiovascular therapies translated into patients before the project end.
The project is partly funded by the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020.
Key Clinicians and Researchers: Chrystos Borantis, Chris Broomhead, Mark Caulfield, John Deanfield, Adam Graham, Mohsin Hussain, Asghar Khaghani, Robert Krams, Pier Lambiase, Chris MacGregor, James Moon, Mike Mullen, Steffen Petersen, Richard Schilling, Andrew Taylor, Arthur Tucker, Simon Woldman
Clinical Transformational Lead: Anthony Mathur